Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer

Detalles Bibliográficos
Autores principales: Bertucci, François, De Nonneville, Alexandre, Finetti, Pascal, Mamessier, Emilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397558/
https://www.ncbi.nlm.nih.gov/pubmed/37278484
http://dx.doi.org/10.1002/cac2.12447
_version_ 1785083939951476736
author Bertucci, François
De Nonneville, Alexandre
Finetti, Pascal
Mamessier, Emilie
author_facet Bertucci, François
De Nonneville, Alexandre
Finetti, Pascal
Mamessier, Emilie
author_sort Bertucci, François
collection PubMed
description
format Online
Article
Text
id pubmed-10397558
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103975582023-08-04 Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer Bertucci, François De Nonneville, Alexandre Finetti, Pascal Mamessier, Emilie Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2023-06-06 /pmc/articles/PMC10397558/ /pubmed/37278484 http://dx.doi.org/10.1002/cac2.12447 Text en © 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Bertucci, François
De Nonneville, Alexandre
Finetti, Pascal
Mamessier, Emilie
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
title Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
title_full Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
title_fullStr Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
title_full_unstemmed Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
title_short Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
title_sort predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in her2‐negative breast cancer
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397558/
https://www.ncbi.nlm.nih.gov/pubmed/37278484
http://dx.doi.org/10.1002/cac2.12447
work_keys_str_mv AT bertuccifrancois predictivepoweroftertiarylymphoidstructuresignatureforneoadjuvantchemotherapyresponseandimmunotherapybenefitinher2negativebreastcancer
AT denonnevillealexandre predictivepoweroftertiarylymphoidstructuresignatureforneoadjuvantchemotherapyresponseandimmunotherapybenefitinher2negativebreastcancer
AT finettipascal predictivepoweroftertiarylymphoidstructuresignatureforneoadjuvantchemotherapyresponseandimmunotherapybenefitinher2negativebreastcancer
AT mamessieremilie predictivepoweroftertiarylymphoidstructuresignatureforneoadjuvantchemotherapyresponseandimmunotherapybenefitinher2negativebreastcancer

Ejemplares similares